Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
The phase 2b Parkinson’s trial missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
Nick Paul Taylor
May 22, 2026 6:12am
Betting on biotech: Prediction markets turn to clinical trials
May 21, 2026 10:30am
Immunovant pays out $39M to call time on 1st-gen FcRn inhibitor
May 20, 2026 8:31am
BioMarin’s $270M Inozyme rare disease bet misses key ph. 3 goal
May 18, 2026 11:05am
Regeneron rocked by failure as melonama drug can't beat Keytruda
May 18, 2026 4:40am
Amgen abandons cancer, Sjögren’s drugs over weak ph.2 data
May 1, 2026 1:45am
